MARKET

CFRX

CFRX

Contrafect Corp
OTCPK
0.069
+0.004
+6.77%
Closed 15:08 12/04 EST
OPEN
0.063
PREV CLOSE
0.065
HIGH
0.069
LOW
0.063
VOLUME
22.00K
TURNOVER
1.51K
52 WEEK HIGH
15.60
52 WEEK LOW
0.044
MARKET CAP
742.91K
P/E (TTM)
-0.0036
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at CFRX last week (1127-1201)?
Weekly Report · 21h ago
Weekly Report: what happened at CFRX last week (1120-1124)?
Weekly Report · 11/27 11:23
Weekly Report: what happened at CFRX last week (1113-1117)?
Weekly Report · 11/20 11:21
Weekly Report: what happened at CFRX last week (1106-1110)?
Weekly Report · 11/13 11:13
Why AMC Entertainment Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Astra space, inc. Shares climbed 59.5% to $1.18 after astra received a non-binding proposal to acquire all of the company's stock. The honest company shares rose 23% following upbeat quarterly results. Affirm holdings shares rose 22.7% after reporting better-than-expected first-quarter results.
Benzinga · 11/09 18:13
Contrafect Corp: Current report
Press release · 11/09 01:35
Weekly Report: what happened at CFRX last week (1030-1103)?
Weekly Report · 11/06 11:18
Contrafect Corp: Prospectus [Rule 424(b)(3)]
Press release · 11/03 22:50
More
About CFRX
ContraFect Corporation is a clinical-stage biotechnology company. The Company is focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. Its lead DLA product candidate, exebacase (CF-301), is used for the treatment of methicillin-resistant S. aureus (MRSA) bloodstream infections (bacteremia), including right-sided endocarditis, when used in addition to standard-of-care (SOC) anti-staphylococcal antibiotics in adult patients. Its CF-301 is being studied in an ongoing Phase Ib/II study in patients with chronic prosthetic joint infections (PJIs) of the knee due to S. aureus or coagulase-negative Staphylococci. Its other product candidate, CF-370, is designed to target a range of gram-negative bacteria, including P. aeruginosa, K. pneumoniae, and A. baumanni, and has demonstrated potent in vivo activity against these pathogens.

Webull offers ContraFect Corp stock information, including OTCPK: CFRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CFRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CFRX stock methods without spending real money on the virtual paper trading platform.